Morningside Ventures leads Series B funding in biotech firm Immune Regulation

Morningside Ventures leads Series B funding in biotech firm Immune Regulation

Laboratory equipment. Photo: Pixabay

22 September, 2020

biotech Immune Regulation Limited Morningside Group Morningside Ventures

Printed by Unregistered user on Sun, 13 Jul 2025 21:08:58 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

Venture Capital

CDH, CMG-SDIC fund co-lead $62m Series C round in Virogin Biotech

Venture Capital

Chinese biotech firm Biocytogen bags $142m Series D+ led by CMB International

Read more from Greater China

Editor’s Take: The Week That Was—July 7-12

Policy & Regulations

Shanghai to consider policy responses to stablecoins, cryptocurrencies